1,721,914 research outputs found
Use of direct oral anticoagulants in patients with atrial fibrillation and obesity or low body weight: the additional contribution to knowledge provided by pharmacokinetic and pharmacodynamic studies
No full text
Cardiac arrest: The need for integrated multi-disciplinary actions for a continuum of care both in acute and at long-term
No full textRun baby run ... but not too fast! Rate control management in atrial fibrillation: a claim for personalization
Full text linkn
Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation
No full textTo the Editor: Pluymaekers et al. (April 18 issue)(1) evaluated the occurrence of spontaneous cardioversion in patients with recent-onset (<36 hours) atrial fibrillation. The proposed wait-and-see approach included cardioversion within 48 hours in the absence of spontaneous resumption of sinus rhythm, and delayed cardioversion was actually necessary in 28% of the patients randomly assigned to this strategy. We think that the idea of waiting for spontaneous cardioversion of atrial fibrillation is interesting, but for practical reasons, better patient targeting would be required. In two previous prospective, randomized trials, we found that in patients with recent-onset atrial fibrillation, spontaneous cardioversion can . .
The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: insights from an individual patient data meta-analysis of COMPANION and CARE-HF
No full textGrey zones in the practice of permanent cardiac pacing: The case of preventive pacing for improving rhythm control in atrial fibrillation
No full textIn memory of Francesco Furlanello: a great advocate for dedicated commitment to effective, up-to-date, and expert management of cardiac arrhythmias and sports cardiology
Full text link
Obesity Paradox in Atrial Fibrillation: Implications for Outcomes and Relationship with Oral Anticoagulant Drugs
No full textIn the last 40 years, concern about the obesity epidemic has increased. Data from the current literature highlight a strong relationship between obesity and atrial fibrillation (AF), particularly in relation to an increased risk for incident and recurrent AF. A phenomenon called the “obesity paradox” has emerged: the apparently counterintuitive evidence from epidemiological data indicating that overweight and obese patients may have a better prognosis than healthy-weight patients. A differential impact of oral anticoagulants (OACs) in terms of effectiveness and safety in the various body mass index categories has been postulated, particularly in the comparison between non-vitamin-K antagonist oral anticoagulants and vitamin K antagonists. This review aims to summarize the evidence on the impact of obesity in patients with AF, focusing on descriptions of the obesity paradox and its relationships with OAC treatment
- …
